China Breast Cancer Diagnostics and Therapeutics Market Trends, Growth, Analysis and Forecast to 2025

China breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 10.2% during the forecast period. Increasing the incidence of breast cancer coupled with a growing awareness program towards breast cancer diagnosis and treatment are the major factors that contributing to the growth of the market. According to the National Central Cancer Registry (NCCR), about 268.6 thousand new cases were estimated in 2015. The breast cancer cases estimated about 189.5 thousand in the urban area and 79 thousand cases in the rural area. Moreover, the mortality by breast cancer was estimated at about 69.5 thousand in the country that further raises the demand for diagnosis and treatment solutions in the country that further propels the market growth.

Get Sample Copy of China Breast Cancer Diagnostics And Therapeutics Market at: https://www.omrglobal.com/request-sample/china-breast-cancer-diagnostics-therapeutics-market

The companies which are contributing to the growth of the China breast cancer diagnostics and therapeutics market include, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Ltd., and others.

China breast cancer diagnostics and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.

For More Information, get A full report of China Breast Cancer Diagnostics And Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/china-breast-cancer-diagnostics-therapeutics-market

The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Market Segmentation

Breast Cancer Diagnostics and Therapeutics Market by Cancer Type

o Ductal Carcinoma In-Situ (DCIS)
o Invasive Ductal Carcinoma (IDC)
o Triple Negative Breast Cancer (TNBC)
o Inflammatory Breast Cancer
o Others (Invasive lobular carcinoma)

Breast Cancer Diagnostics and Therapeutics Market by Diagnostics

o Mammography
o Biopsy
o PET/CET
o Ultrasound
o Others (MRI)

Breast Cancer Diagnostics and Therapeutics Market by Therapeutics

o Chemotherapy
o Hormone Therapy
o Targeted Therapy
o Others (Radiation Therapy, Surgery)

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/china-breast-cancer-diagnostics-therapeutics-market

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 7803040404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

This release was published on openPR.